Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine plus aripiprazole/brexpiprazole in treatment‑resistant depression
jRCTs051210192Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: CADSS. Started Mar 2022; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCTs051210192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210192.